As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of BriaCell Therapeutics Corp. The largest reported stake is Plambeck Jeremy Myung Jae's, at 100%. 6 filings are on record since July 21, 2025 (Schedule 13G, October 10, 2025).
Sell to companies like BriaCell Therapeutics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Citadel Advisors LLC · Sole voting: 0 · Shared voting: 716,699 · Sole dispositive: 0 · Shared dispositive: 716,699 · SCHEDULE 13G, 2026-01-23
- · Reporting person: CVI Investments, Inc. · Sole voting: 0 · Shared voting: 98,944 · Sole dispositive: 0 · Shared dispositive: 98,944 · SCHEDULE 13G/A, 2025-11-07
- · Reporting person: Plambeck Jeremy Myung Jae · Sole voting: 4,330 · Shared voting: 0 · Sole dispositive: 4,330 · Shared dispositive: 0 · SCHEDULE 13G, 2025-10-10
- · Reporting person: Iroquois Capital Management, LLC · Sole voting: 0 · Shared voting: 560,000 · Sole dispositive: 0 · Shared dispositive: 560,000 · SCHEDULE 13G, 2025-07-28
- · Holder: CVI Investments, Inc. · Percent: 5.7% · SCHEDULE 13G
BriaCell Therapeutics Corp. has 6 Schedule 13D or 13G filings on record since 2025-07-21. 3 holders' latest filing reports 5% or more of common shares, no par value per share (the "shares"). Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 100% | 13,339 | SCHEDULE 13G, 2025-10-10 | 2025-08-25 | |
| 9.99% | 717,198 | SCHEDULE 13G, 2026-01-23 | 2026-01-15 | |
| 9.1% | 1,600,000 | SCHEDULE 13G, 2025-07-28 | 2025-07-15 | |
| CVI Investments, Inc. | 4.9% | 98,944 | SCHEDULE 13G/A, 2025-11-07 | 2025-09-30 |
Holding shares or following this stake? See who's behind BriaCell Therapeutics Corp. and the warning signs.
Free to see. No signup.
Keep reading
More on BriaCell Therapeutics Corp. and the records around it.
BriaCell Therapeutics Corp. elsewhere on the record
- IPO filing Jan 2026
- Who owns it
Companies that share a holder
- Iroquois Capital Management, LLC also filed stake reports on 13 other companies: 22nd Century Group (Aug 2026), XWELL, Inc. (Aug 2026), Clearmind Medicine Inc. (Aug 2026)
- CVI Investments, Inc. also filed stake reports on 48 other companies: Pine Tree Acquisition Corp. (Oct 2026), Sunshine Biopharma Inc. (Oct 2026), Outlook Therapeutics, Inc. (Aug 2026)
- Citadel Advisors LLC also filed stake reports on 58 other companies: Quantinuum Inc. (Oct 2026), REALLOYS INC. (Oct 2026), STARFIGHTERS SPACE, INC. (Oct 2026)
Watch BriaCell Therapeutics Corp.
Get an email when BriaCell Therapeutics Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BriaCell Therapeutics Corp.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BriaCell Therapeutics Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BriaCell Therapeutics Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Plambeck Jeremy Myung Jae | 4,330 | 0 | 4,330 | 0 | SCHEDULE 13G, 2025-10-10 |
| Citadel Advisors LLC | 0 | 716,699 | 0 | 716,699 | SCHEDULE 13G, 2026-01-23 |
| Citadel Advisors Holdings LP | 0 | 716,699 | 0 | 716,699 | SCHEDULE 13G, 2026-01-23 |
| Citadel GP LLC | 0 | 716,699 | 0 | 716,699 | SCHEDULE 13G, 2026-01-23 |
| Citadel Securities LLC | 0 | 499 | 0 | 499 | SCHEDULE 13G, 2026-01-23 |
| Citadel Securities Group LP | 0 | 499 | 0 | 499 | SCHEDULE 13G, 2026-01-23 |
| Citadel Securities GP LLC | 0 | 499 | 0 | 499 | SCHEDULE 13G, 2026-01-23 |
| Kenneth Griffin | 0 | 717,198 | 0 | 717,198 | SCHEDULE 13G, 2026-01-23 |
| Iroquois Capital Management, LLC | 0 | 560,000 | 0 | 560,000 | SCHEDULE 13G, 2025-07-28 |
| Richard Abbe | 1,040,000 | 560,000 | 1,040,000 | 560,000 | SCHEDULE 13G, 2025-07-28 |
| Kimberly Page | 0 | 560,000 | 0 | 560,000 | SCHEDULE 13G, 2025-07-28 |
| CVI Investments, Inc. | 0 | 98,944 | 0 | 98,944 | SCHEDULE 13G/A, 2025-11-07 |
| Heights Capital Management, Inc. | 0 | 98,944 | 0 | 98,944 | SCHEDULE 13G/A, 2025-11-07 |
The latest filing names BriaCell Therapeutics Corp., with its principal executive office as Suite 300-235 15th Street, West Vancouver (SCHEDULE 13G, 2026-01-23).
What the percentages are based on
Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of the date of the event which requires filing of this statement and is incorporated herein by reference.Richard Abbe, SCHEDULE 13G, 2025-07-28
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-21 | CVI Investments, Inc. | 4.9% | SCHEDULE 13G/A |
| 2025-07-22 | CVI Investments, Inc. | 5.7% | SCHEDULE 13G |
| 2025-07-28 | Richard Abbe | 9.1% | SCHEDULE 13G |
| 2025-10-10 | Plambeck Jeremy Myung Jae | 100% | SCHEDULE 13G |
| 2025-11-07 | CVI Investments, Inc. | 4.9% | SCHEDULE 13G/A |
| 2026-01-23 | Kenneth Griffin | 9.99% | SCHEDULE 13G |
Questions about who owns BriaCell Therapeutics Corp.
Who owns BriaCell Therapeutics Corp.?
On this page, 3 holders' latest ownership filings report 5% or more of BriaCell Therapeutics Corp.: Plambeck Jeremy Myung Jae (100%, Schedule 13G, filed 2025-10-10), Kenneth Griffin (9.99%, Schedule 13G, filed 2026-01-23) and Richard Abbe (9.1%, Schedule 13G, filed 2025-07-28).
Who are the largest shareholders of BriaCell Therapeutics Corp.?
By the share each holder's latest filing reports, the largest holders of BriaCell Therapeutics Corp. on this page are Plambeck Jeremy Myung Jae (100%), Kenneth Griffin (9.99%) and Richard Abbe (9.1%).
When did Plambeck Jeremy Myung Jae buy into BriaCell Therapeutics Corp.?
The filings give report dates, not purchase dates. The earliest filing from Plambeck Jeremy Myung Jae on this page is the Schedule 13G, filed 2025-10-10, reporting 100%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for BriaCell Therapeutics Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| January 14, 2026 | IPO filing, Form 424B4 | $5.59 a share | IPO filings | Source |
| December 23, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| July 16, 2025 | IPO filing, Form 424B4 | $1.25 a share | IPO filings | Source |
| July 10, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| July 9, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| July 8, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| April 28, 2025 | IPO filing, Form 424B4 | $4.5 a share | IPO filings | Source |
| April 28, 2025 | IPO filing, Form 424B4 | $4.5 a share | IPO filings | Source |
| April 23, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| April 22, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for BriaCell Therapeutics Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.